Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial

BACKGROUND: Treatment of acute respiratory distress syndrome (ARDS) associated with COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive mechanical ventilation, and remains associated with high mortality. Given their ability to limit inflammation, induce immune cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Grégoire, Céline, Layios, Nathalie, Lambermont, Bernard, Lechanteur, Chantal, Briquet, Alexandra, Bettonville, Virginie, Baudoux, Etienne, Thys, Marie, Dardenne, Nadia, Misset, Benoît, Beguin, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291273/
https://www.ncbi.nlm.nih.gov/pubmed/35860245
http://dx.doi.org/10.3389/fimmu.2022.932360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291273/
https://www.ncbi.nlm.nih.gov/pubmed/35860245
http://dx.doi.org/10.3389/fimmu.2022.932360

Ejemplares similares